Advertisement
DSGN vs RNA
Which Stock Would AI Choose? Design Therapeutics (DSGN) vs. Avidity Biosciences (RNA) Stock Comparison
Key Takeaways
- Different science, same sector: DSGN (Design Therapeutics) uses a small-molecule GeneTAC platform, while RNA (Avidity Biosciences) develops antibody oligonucleotide conjugate (AOC) RNA therapeutics.
- Corporate status diverges: RNA became a wholly owned subsidiary of Novartis in February 2026, while DSGN remains an independent clinical-stage company.
- Pipeline stage differs: RNA has multiple late-stage (Phase 3) programs and planned regulatory filings, whereas DSGN's lead program is in earlier Phase 1/2 development.
- Relative performance has diverged: DSGN posted strong 52-week gains and fresh analyst upgrades, while RNA shares traded well below their 52-week high amid acquisition-related restructuring.
- Financial scale varies: RNA reported roughly $1.9 billion in cash as of late 2025, versus a more modest cash position of over $200 million for DSGN.
Introduction
Design Therapeutics and Avidity Biosciences both operate in the biotechnology sector, yet they pursue fundamentally different strategies for treating genetic and rare diseases. This stock comparison is relevant for healthcare investors and traders evaluating two clinical-stage companies at different points of development and corporate maturity. While both names carry the characteristic risk and volatility of pre-revenue biotech, their divergent business models, pipeline stages, and recent corporate events create distinct market positioning. Understanding how DSGN and RNA compare on momentum, catalysts, and risk can help market participants assess which profile better aligns with their objectives.
DSGN Overview and Recent Performance
DSGN, Design Therapeutics, is a clinical-stage biopharmaceutical company based in Carlsbad, California. It uses its proprietary GeneTAC platform to develop small-molecule, gene-targeted chimera candidates designed to address the root cause of diseases driven by inherited nucleotide repeat expansions. Its pipeline centers on Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), myotonic dystrophy type 1 (DM1), and Huntington's disease.
In recent market activity, DSGN has drawn renewed attention from the analyst community. Wells Fargo initiated coverage with an Overweight rating and a $26 price target in early October 2026, citing the potential of the lead candidate DT-216P2 in Friedreich ataxia. Earlier coverage from Jefferies (Buy) and upgrades from RBC Capital and Leerink Partners to Outperform also reflect a more constructive sentiment shift. Shares have posted a strong 52-week advance, though the stock has pulled back in recent weeks from its recent highs. Catalysts on the near horizon include a registrational-path update for DT-216P2 and 12-week efficacy data from the RESTORE-FA study expected in early 2027.
RNA Overview and Recent Performance
RNA, Avidity Biosciences, is a San Diego-based biopharmaceutical company developing RNA-targeted therapies for rare neuromuscular diseases using its AOC (antibody oligonucleotide conjugate) platform. The company's three lead programs are del-desiran for DM1, del-zota for Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping, and del-brax for facioscapulohumeral muscular dystrophy (FSHD).
A defining recent event is corporate rather than clinical: Novartis announced an agreement to acquire Avidity in October 2025, and the transaction closed in February 2026, making Avidity an indirect, wholly owned subsidiary. A related SpinCo separation was structured to carve out certain programs. On the clinical front, Avidity has advanced late-stage trials and planned a Biologics License Application (BLA) submission for del-zota. Financially, the company reported roughly $1.9 billion in cash and marketable securities as of late September 2025. In recent market activity, RNA shares have traded well below their 52-week high, reflecting the acquisition price dynamics and the restructuring of the company's equity structure.
Trending AI Robots
For traders seeking a more systematic approach to stocks like DSGN and RNA, Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, statistics, and target list of securities. Only the bots best suited to current market conditions earn a place in the Trending AI Robots section, making it a practical starting point for those who prefer algorithm-driven signals over manual analysis. Exploring the Trending AI Robots can help investors see how automated strategies are positioning across volatile sectors such as biotechnology.
Head-to-Head Comparison
The clearest contrast between these two names is their therapeutic approach and stage of development. DSGN relies on small molecules designed to be simpler to manufacture and deliver than genetic medicines, but its lead program remains in Phase 1/2, meaning key efficacy milestones are still ahead. RNA operates further along the development curve, with Phase 3 programs and regulatory submissions in progress, which historically reduces binary clinical risk relative to earlier-stage peers.
Corporate structure introduces another trade-off. RNA's acquisition by Novartis provides capital and commercialization scale but has changed the investment profile, as the share price now reflects deal and SpinCo dynamics rather than purely standalone pipeline fundamentals. DSGN, by contrast, remains a pure-play independent biotech, giving investors direct exposure to its clinical catalysts but also to concentrated execution risk.
On momentum and sentiment, DSGN has enjoyed a favorable stretch of analyst initiations and upgrades tied to its Friedreich ataxia data, supporting its strong 52-week performance. RNA's relative performance has been pressured by the acquisition-related revaluation. Risk factors differ accordingly: DSGN faces clinical and cash-runway considerations with a smaller balance sheet, while RNA faces integration, restructuring, and post-transaction uncertainty despite a substantially larger cash position.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor DSGN in the current environment. The stock has demonstrated more consistent relative momentum over the past year, supported by repeated analyst upgrades and a near-term slate of defined catalysts around its lead Friedreich ataxia program. By contrast, RNA carries stronger late-stage fundamentals and a larger capital base, but its trend has been clouded by the Novartis acquisition and SpinCo restructuring, which introduces complexity into its market positioning. A trend-following model would likely weigh DSGN's cleaner, catalyst-rich setup more favorably, while acknowledging that RNA's later-stage pipeline could reassert itself as clarity around the corporate structure improves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DSGN is a Hold and RNA is a StrongBuy.
DSGN in downward trend: 10-day moving average crossed below 50-day moving average on September 18, 2026
The 10-day moving average for DSGN crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DSGN as a result. In 73 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DSGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for DSGN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DSGN's RSI Oscillator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 57 cases where DSGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for DSGN just turned positive on October 21, 2026. Looking at past instances where DSGN's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where DSGN advanced for three days, in 271 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
DSGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. DSGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.252) is normal, around the industry mean (2.973). P/E Ratio (-8.890) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DSGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RNA sees its Stochastic Oscillator ascends from oversold territory
On October 21, 2026, the Stochastic Oscillator for RNA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 49 instances where the indicator left the oversold zone. In 43 of the 49 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNA's RSI Indicator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on RNA as a result. In 64 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for RNA just turned positive on October 07, 2026. Looking at past instances where RNA's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in 197 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for RNA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.638) is normal, around the industry mean (2.988). P/E Ratio (-1.471) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (4.537) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RNA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 85 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| DSGN | RNA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 80% | 2 days ago 82% |
| Stochastic ODDS (%) | 1 day ago 82% | 2 days ago 88% |
| Momentum ODDS (%) | 1 day ago 77% | 2 days ago 75% |
| MACD ODDS (%) | 1 day ago 87% | 2 days ago 85% |
| TrendWeek ODDS (%) | 1 day ago 88% | 2 days ago 80% |
| TrendMonth ODDS (%) | 1 day ago 78% | 2 days ago 84% |
| Advances ODDS (%) | 3 days ago 88% | 2 days ago 78% |
| Declines ODDS (%) | 1 day ago 80% | 4 days ago 83% |
| BollingerBands ODDS (%) | 1 day ago 88% | N/A |
| Aroon ODDS (%) | 1 day ago 73% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DSGN’s FA Score shows that 1 FA rating(s) are green while RNA’s FA Score has 1 green FA rating(s).
- DSGN’s FA Score: 1 green, 4 red.
- RNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DSGN’s TA Score shows that 5 TA indicator(s) are bullish while RNA’s TA Score has 5 bullish TA indicator(s).
- DSGN’s TA Score: 5 bullish, 4 bearish.
- RNA’s TA Score: 5 bullish, 2 bearish.
Price Growth
DSGN (@Biotechnology) experienced а +10.28% price change this week, while RNA (@Biotechnology) price change was +4.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
DSGN is expected to report earnings on Nov 04, 2026.
RNA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DSGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, DSGN has been loosely correlated with RNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if DSGN jumps, then RNA could also see price increases.
| Ticker / NAME | Correlation To DSGN | 1D Price Change % | ||
|---|---|---|---|---|
| DSGN | 100% | -2.24% | ||
| RNA - DSGN | 48% Loosely correlated | +2.00% | ||
| TSHA - DSGN | 45% Loosely correlated | -2.79% | ||
| FDMT - DSGN | 43% Loosely correlated | -6.10% | ||
| LXEO - DSGN | 42% Loosely correlated | -3.67% | ||
| RCKT - DSGN | 42% Loosely correlated | +5.00% | ||
More | ||||